Nivolumab for Relapsed/Refractory Classic Hodgkin Lymphoma After Failure of Autologous Hematopoietic Cell Transplantation: Extended Follow-Up of the Multicohort Single-Arm Phase II CheckMate 205 Trial

PURPOSE: Genetic alterations causing overexpression of programmed death-1 ligands are near universal in classic Hodgkin lymphoma (cHL). Nivolumab, a programmed death-1 checkpoint inhibitor, demonstrated efficacy in relapsed/refractory cHL after autologous hematopoietic cell transplantation (auto-HCT...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Clin Oncol
Main Authors: Armand, Philippe, Engert, Andreas, Younes, Anas, Fanale, Michelle, Santoro, Armando, Zinzani, Pier Luigi, Timmerman, John M., Collins, Graham P., Ramchandren, Radhakrishnan, Cohen, Jonathon B., De Boer, Jan Paul, Kuruvilla, John, Savage, Kerry J., Trneny, Marek, Shipp, Margaret A., Kato, Kazunobu, Sumbul, Anne, Farsaci, Benedetto, Ansell, Stephen M.
Formato: Artigo
Idioma:Inglês
Publicado em: American Society of Clinical Oncology 2018
Assuntos:
ORIGINAL REPORTS
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6075855/
https://ncbi.nlm.nih.gov/pubmed/29584546
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2017.76.0793
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados